Crinetics Pharmaceuticals Inc

Financials

Cash from operating activities -62.03 M-88.59 M-115.2 M-166.31 M-225.97 M377.92 M -192.12 M Cash from investing activities 217 K-56.48 M-173.98 M-200.41 M-574.82 M173.91 M 173.91 M Cash from financing activities 114.57 M252.68 M121.96 M388.94 M1.01 B40.61 M 40.61 M Free cash flow -62.21 M-89.02 M-116.86 M-171 M-229.81 M372.16 M -197.88 M

Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.

CRNX

Financials

Crinetics Pharmaceuticals Inc

Haberler

Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates

Crinetics Pharma kazancı $0,05 ile beklentilere göre daha iyi, kâr ise beklentilere göre yüksek

Crinetics Pharma earnings beat by $0.05, revenue topped estimates

Crinetics kazanç raporu: İlaç lansmanı artan zararları dengeleyebilir mi?

Crinetics earnings on deck: Can drug launch offset mounting losses?

Morgan Stanley’e Göre Takip Edilmesi Gereken En İyi SMID Cap Biyoteknoloji Hisseleri

Top SMID Cap Biotech Stocks to Watch According to Morgan Stanley

Crinetics Pharmaceuticals, Jeff Knight’ın yönetici unvanını ve sorumluluklarını güncelledi

Crinetics Pharmaceuticals updates Jeff Knight’s executive title and responsibilities

Crinetics begins phase 2/3 trial of oral CAH treatment in children

XPH: Healthcare Dashboard For January (NYSEARCA:XPH)